KKR to acquire Biotage for SEK11.6bn.

KKR, a global investment firm, offered to acquire Biotage, a drug discovery and development, diagnostics and analytical testing solutions provider, for SEK11.6bn. "We see a need for a strategic repositioning of Biotage to ensure future growth and value creation. We believe this strategic development is better done in a private setting while expanding further into new product areas in order to build a broader platform, organically or through M&A. KKR has a deep understanding of the sector, the markets, the company and its products, and can provide the support, resources and long-term perspective needed for Biotage and its management to embark on the next phase of its journey," Kugan Sathiyanandarajah, KKR Partner.